5 recruiting, 3 completed, 2 not yet recruiting, 1 active not recruiting. 12 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Recruiting 5, Completed 3, Not yet recruiting 2, Active not recruiting 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow HPV Infection: new trials by email Literature Review of HPV Infection trials Research Report on HPV Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adjuvant 5-Fluorouracil Following Thermal Ablation to Improve HPV Treatment Outcomes in Women With HIV in Kenya 5% 5-fluorouracil Topical Cream, Placebo Cream - HIV Infections, HPV Infection | Phase 2 | Not yet recruiting | UNC Lineberger Comprehensive Cancer Center | 140 | 2026-09-01 | 2026-08-27 |
| Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+ pBI-11 (3 doses), pBI-11 (1 dose), Placebo (2 doses) - HPV Infection | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 48 | 2026-06-25 | 2026-07-01 |
| Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities EGCG and Quinine Sulfate Vaginal Suppository, Placebo - High-risk HPV (Any Strain), LSIL, Low Grade Squamous Intraepithelial Lesion | Phase 2 | Recruiting | Amplexd Therapeutics, Inc. | 45 | 2026-04-30 | 2026-05-14 |
| To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years Medium dose for 15-HPV vaccine, High dose for 15-HPV vaccine, Placebo - HPV Infection, HPV-Related Carcinoma | Phase 2 | Recruiting | Shanghai Bovax Biotechnology Co., Ltd. | 330 | 2025-01-15 | 2025-12-17 |
| Effector and Memory Immune Responses to HPV Vaccination in Vietnamese Women Post Virus Exposure Human papillomavirus 9-valent vaccine, Recombinant - HPV Infection, Cervical Cancer | Phase 2 | Not yet recruiting | National Institute of Hygiene and Epidemiology, Vietnam | 300 | 2024-12-14 | 2024-11-08 |
| Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3) Artesunate ointment, Placebo ointment - Vulvar Diseases, HPV Infection | Phase 2 | Recruiting | Frantz Viral Therapeutics, LLC | 27 | 2023-12-06 | 2025-08-14 |
| Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL Artesunate, Placebo - Anal High Grade Squamous Intraepithelial Lesion, Anal Precancerous Condition | Phase 2 | Active not recruiting | Frantz Viral Therapeutics, LLC | 17 | 2023-02-10 | 2025-05-18 |
| Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions ChAdOx1-HPV, MVA-HPV, Placebo - HPV Infection, CIN1 | Phase 1 / Phase 2 | Completed | Barinthus Biotherapeutics | 108 | 2021-03-16 | 2025-08-28 |
| Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3) Artesunate vaginal insert, Placebo vaginal insert - CIN 2/3, HPV Infection | Phase 2 | Recruiting | Frantz Viral Therapeutics, LLC | 78 | 2020-09-09 | 2025-10-02 |
| Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) Biological/Vaccine: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha), 9-valent HPV vaccine（Gardasil 9） - HPV Infection, HPV-Related Cervical Carcinoma | Phase 2 | Completed | National Vaccine and Serum Institute, China | 480 | 2020-06-20 | 2022-05-06 |
| Yallaferon in Chinese Population Recombinant Human Interferon a-2b Gel, Placebo - HPV Infection | Phase 2 | Unknown | Lee's Pharmaceutical Limited | 100 | 2015-09-01 | 2015-11-02 |
| Recombinant Human Interferon a-2b Gel for HPV Gynecological Infections Yallaferon® - HPV Infection | Phase 2 / Phase 3 | Completed | Lee's Pharmaceutical Limited | 325 | 2011-03-01 | 2013-04-05 |
Papillomavirus Infections (12) · Uterine Cervical Dysplasia (3) · Condylomata Acuminata (2) · Uterine Cervical Neoplasms (2) · Atypical Squamous Cells of the Cervix (1) · HIV Infections (1) · Squamous Intraepithelial Lesions (1) · Vulvar Diseases (1)
Communicable Diseases (12) · DNA Virus Infections (12) · Disease Attributes (12) · Genital Diseases (12) · Infections (12) · Pathologic Processes (12) · Pathological Conditions, Signs and Symptoms (12) · Sexually Transmitted Diseases (12) · Sexually Transmitted Diseases, Viral (12) · Tumor Virus Infections (12) · Urogenital Diseases (12) · Virus Diseases (12) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Genital Diseases, Female (5)
artemisinin (3) · artesunic acid (3) · artenimol (2) · Artesunate (1) · Biological Products (1) · Human Papillomavirus Recombinant Vaccine nonavalent (1) · epigallocatechin gallate (1)
Frantz Viral Therapeutics, LLC (3) · Lee's Pharmaceutical Limited (2) · Amplexd Therapeutics, Inc. (1) · Barinthus Biotherapeutics (1) · National Institute of Hygiene and Epidemiology, Vietnam (1) · National Vaccine and Serum Institute, China (1) · Shanghai Bovax Biotechnology Co., Ltd. (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · UNC Lineberger Comprehensive Cancer Center (1)
United States (4) · China (3) · Australia (1) · Belgium (1) · Estonia (1) · Hong Kong (1) · Kenya (1) · United Kingdom (1) · Vietnam (1)
Chemtai Mungo, MD, MPH (1) · Hong T Duong, MD, PhD (1) · Joel Palefsky, MD (1) · Kar Kei Yung, MBBS (HK), MRCOG, FHKCOG, FHKA (1) · Kimberly Levinson, MD (1) · Trang V Nguyen, PhD (1) · Tuan A Le, MD, PhD (1) · Yi Mo, Master (1)
PMID 18433504, PMID 22306855, PMID 23632723, PMID 34517047, PMID 34972721, PMID 36817494, PMID 41403292
P50CA098252 (1), R37CA306827 (1)